NFκB1: a common biomarker linking Alzheimer's and Parkinson's disease pathology
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Alzheimer's disease (AD) and Parkinson's disease (PD) are neurodegenerative disorders characterized by mitochondrial dysfunction and chronic inflammation. The transcription factor NF-κB1 is implicated in both neuroprotective and pro-inflammatory processes, with its activity varying between neurons and glial cells. While previous studies have explored the genetic and epigenetic contributions to these diseases, the infection hypothesis has re-emerged as a potential framework for identifying novel biomarkers and therapeutic targets. Methods: = 3). Differential gene expression analysis and pathway enrichment were performed to identify dysregulated signaling mechanisms relevant to neuroinflammation and mitochondrial function. Results and discussion: TNFα signaling through the NF-κB pathway was identified as a prominently dysregulated mechanism in both AD and PD samples. Transcript levels of NFE2L2 (NRF2) and NF-κB1 were elevated, coinciding with reduced expression of the mitochondrial transporter gene SLC25A6, suggesting a compensatory response to oxidative stress. Additionally, PLCG2 expression was markedly increased in microglial populations, reflecting heightened immune activation. A significant 10-fold reduction in hemoglobin subunit alpha (HbA1) RNA was observed in disease groups compared to controls, indicating compromised oxygen transport and cellular stress. These findings highlight candidate biomarkers and suggest that therapeutic strategies targeting mitochondrial integrity and neuroinflammation may be effective in AD and PD.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- NFκB1: a common biomarker linking Alzheimer's and Parkinson's disease pathology
- Date Crossref
- 06/05/2025
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Marshall University Department of Biomedical Engineering pays non établi dans la noticeUniversité ou école supérieure
-
Brown University Department of Pathology and Laboratory Medicine pays non établi dans la noticeUniversité ou école supérieure
-
SouthCoast Health pays non établi dans la noticeÉtablissement de santé
-
Brigham and Women's Hospital Department of Anesthesiology pays non établi dans la noticeÉtablissement de santé
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins University pays non établi dans la noticeUniversité ou école supérieure
-
Department of Cardiothoracic Surgery pays non établi dans la noticeInstitution
-
Johns Hopkins School of Medicine Department of Neurology pays non établi dans la noticeUniversité ou école supérieure
Department of Biomedical Engineering — Marshall University, Department of Pathology and Laboratory Medicine — Brown University et SouthCoast Health, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.